Comparison of the prognostic value of different inflammation-based scores in patients with hepatocellular carcinoma after Lenvatinib therapy

Figure 1 Kaplan-Meier curves of the overall survival of hepatocellular carcinoma patients after Lenvatinib therapy. A: C-reactive protein; B: C-reactive protein-to-albumin ratio; C: Lymphocyte-to-C-reactive protein ratio; D: Lymphocyte-to-monocyte ratio; E: Neutrophil-to-lymphocyte ratio; F: Platelet-to-lymphocyte ratio; G: Prognostic nutritional index; H: Systemic immune-inflammation index. CRP: C-reactive protein; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; LCR: Lymphocyte-to-C-reactive protein ratio; LMR: Lymphocyte-to-monocyte ratio; SII: Systemic immune-inflammation index; CAR: C-reactive protein-to-albumin ratio; PNI: Prognostic nutritional index.